Alternative chemotherapy for acute myeloid leukemia with Down syndrome

Gregory Joey, Yuke Nelwan, Max Franz Joseph Mantik, Stefanus Gunawan, Valerie de Haas, Gertjan L. Kaspers

Research output: Contribution to journalArticlepeer-review


Myeloid leukemia with Down syndrome (ML-DS) is a unique entity of acute myeloid leukemia (AML) with superior treatment response and overall survival compared with children with AML. However, despite the advances in treatment approaches, ML-DS survival rates for children in low- and middle-income countries remain poor. In this article, we describe 3 cases of ML-DS, which were treated with a novel protocol using vincristine, cytarabine, and daunorubicin plus triple intrathecal drugs. All the 3 patients successfully finished the treatment, with 2 patients in complete remission until now. One patient died because of uncontrolled bleeding for 2 days after finishing the chemotherapy regimen. Our findings indicate that using our treatment protocol, ML-DS is treatable in limited-resource settings such as that in Manado, Indonesia.

Original languageEnglish
Article number00001
JournalEuropean Journal of Oncology Pharmacy
Issue number3
Publication statusPublished - 1 Sept 2022


  • Acute myeloid leukemia
  • Down syndrome
  • GATA1
  • Prognosis
  • Treatment


Dive into the research topics of 'Alternative chemotherapy for acute myeloid leukemia with Down syndrome'. Together they form a unique fingerprint.

Cite this